The board of directors of Genscript Biotech Corporation announced to the shareholders of the company and potential investors that, based on the latest review of the unaudited management accounts of the Group for the year ended December 31, 2015 and the information currently available to the Group, the Group is expected to record a significant increase in the net profit for the year ended December 31, 2015, as compared to the year ended December 31, 2014, mainly due to a substantial gain arising from the settlement of the dispute in connection with the U.S. Lawsuit.